To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
This chapter describes Rwanda’s record within the manufacturing sector. Until recently, the Rwandan Patriotic Front (RPF) did not prioritise manufacturing-based growth because of the high transport costs associated with its landlocked geographical position. While there has been some attempt at refocusing on industrial policy since 2015, because of a rising trade deficit and the urgent need to create employment, there has not been substantial progress. Rwanda has not achieved significant advances in increasing industrial employment, production and exports. After presenting the evolution of Rwanda’s industrial policy, the chapter provides detailed examples of three sectors: apparels (textiles and garments), construction materials and pharmaceuticals. In line with dynamics in other sectors, domestic capital has been marginalised in favour of supporting RPF-affiliated firms or relying on foreign investors. Some foreign investors like Volkswagen and BioNTech have invested in Rwanda with much fanfare, but most success has been driven by RPF-affiliated firms. Rwanda’s hopes for structural transformation fall at a key domestic hurdle: building effective state–business relationships aimed at technological capability acquisition for latecomer firms.
In the years following FDA approval of direct-to-consumer, genetic-health-risk/DTCGHR testing, millions of people in the US have sent their DNA to companies to receive personal genome health risk information without physician or other learned medical professional involvement. In Personal Genome Medicine, Michael J. Malinowski examines the ethical, legal, and social implications of this development. Drawing from the past and present of medicine in the US, Malinowski applies law, policy, public and private sector practices, and governing norms to analyze the commercial personal genome sequencing and testing sectors and to assess their impact on the future of US medicine. Written in relatable and accessible language, the book also proposes regulatory reforms for government and medical professionals that will enable technological advancements while maintaining personal and public health standards.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.